Evaluation of Piperine Against Cancer Stem Cells (CSCs) of Hepatocellular Carcinoma: Insights into Epithelial-mesenchymal Transition (EMT)
Overview
Chemistry
Affiliations
Cancer stem cells (CSCs) are involved in recurrent hepatocellular carcinoma (HCC), yet there is a lack of effective treatment that targets these CSCs. CD44+ and CD133+ CSCs are markedly expressed in HepG2 cells and were isolated and characterized using fluorescence-activated cell sorting (FACS) analysis. Since piperine is known as an effective molecule against metastasis, we thought to investigate the effect of piperine against CD44+/CD133+ CSCs. Herein, piperine was found to be active against these CSCs. Also, it was found appropriate to respite at the 'subG/G and G/G' phase of the cell cycle analysis, respectively. TGF-β activated epithelial-mesenchymal transition (EMT) has been involved in the invasion and metastasis of HepG2 cells in hepatocellular carcinoma. Therefore, we next investigated the effect of piperine on different biomarkers that remarkably takes part in the process of EMT using flow cytometric analysis. Piperine was found able to repress the epithelial marker (E-cadherin) but was unable to restore the level of Vimentin (mesenchymal marker) and SNAIL (EMT-inducing transcription factor). Therefore, the findings of this study revealed that piperine could be an effective treatment strategy for recurrent hepatocarcinogenesis.
Stigmasterol Attenuates Triple-negative Breast Cancer Stem Cell Properties by Inhibiting JAK3.
Zhou R, Zhang Y, Xu L, Sun Y J Cancer. 2025; 16(5):1618-1630.
PMID: 39991585 PMC: 11843247. DOI: 10.7150/jca.94822.
Sravani A, Thomas J Heliyon. 2025; 11(3):e41964.
PMID: 39959483 PMC: 11830326. DOI: 10.1016/j.heliyon.2025.e41964.
Sayilan Ozgun G, Ozgun E, Karabas T, Suer Gokmen S, Eskiocak S Naunyn Schmiedebergs Arch Pharmacol. 2024; .
PMID: 39708099 DOI: 10.1007/s00210-024-03725-0.
Hakeem A, El-Kersh D, Hammam O, Elhosseiny A, Zaki A, Kamel K Sci Rep. 2024; 14(1):18181.
PMID: 39107323 PMC: 11303729. DOI: 10.1038/s41598-024-65508-0.
Alhudaithi S, Kalam M, Binobaid L, Ali R, Almutairi M, Qamar W Saudi Pharm J. 2024; 32(5):102064.
PMID: 38633710 PMC: 11022100. DOI: 10.1016/j.jsps.2024.102064.